Retinal gene therapy company Nightstar scores $45 mln Series C
London-based Nightstar, a retinal gene therapy company, has closed $45 million in Series C financing. The backers were Wellington Management Company, Redmile Group, Syncona and New Enterprise Associates.
5 July 2017•1 min read
